Pazopanib in the treatment of advanced renal cell carcinoma

Pazopanib is an oral multitargeted tyrozine kinase inhibitor that is used in advanced renal cancer in most countries of the world. Pazopanib inhibits tyrosine kinase receptors involved in tumor angiogenesis and proliferation, including VEGF, platelet-derived growth factor (PDGF) and stem cell growth...

Full description

Bibliographic Details

Published in:	Медицинский совет
Main Authors:	M. I. Volkova, A. S. Olshanskaya
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2018-11-01
Subjects:	pazopanib sorafenib sunitinib axitinib bevacizumab everolimus disseminated renal cell carcinoma targeted therapy survival
Online Access:	https://www.med-sovet.pro/jour/article/view/2753